Akebia Therapeutics (AKBA) Change in Account Payables (2015 - 2026)
Akebia Therapeutics (AKBA) posted quarterly Change in Account Payables of -$7.8 million for Q1 2026, down 248.79% year-over-year from $5.2 million in Q1 2025, and down 174.79% quarter-over-quarter from $10.4 million in Q4 2025.
Akebia Therapeutics (AKBA) Change in Account Payables (2015 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Change in Account Payables for 12 consecutive years, with -$7.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables fell 248.79% year-over-year to -$7.8 million; the TTM figure through Mar 2026 stood at -$2.5 million (down 163.44% YoY), while the FY2025 annual figure was $3.1 million, up 325.95% from the prior year.
- Change in Account Payables retreated to -$7.8 million in Q1 2026 per AKBA's latest filing, from $10.4 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $18.9 million in Q4 2022 and bottomed at -$9.0 million in Q1 2023.
- Historically, Change in Account Payables has averaged -$577470.6 across 5 years, with a median of -$2.2 million in 2025.
- Annual changes were most pronounced in 2022 — Change in Account Payables soared 491.65% — and 2026, when it tumbled 248.79%.
- Akebia Therapeutics' Change in Account Payables stood at $18.9 million in 2022, then tumbled by 76.2% to $4.5 million in 2023, then sank by 46.84% to $2.4 million in 2024, then surged by 335.21% to $10.4 million in 2025, then tumbled by 174.79% to -$7.8 million in 2026.
- Business Quant data shows AKBA's Change in Account Payables at -$7.8 million in Q1 2026, $10.4 million in Q4 2025, and -$8.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -53.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -143.74 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -21.20 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Akebia Therapeutics | 249.25 Mn | 93.70 Mn | 38.70 Mn | 2.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.60 Mn |
| Jun 30, 2026 | 2.60 Mn |
| Mar 31, 2026 | -7.79 Mn |
| Mar 31, 2026 | -7.79 Mn |
| Dec 31, 2025 | 10.42 Mn |
| Dec 31, 2025 | 10.42 Mn |
| Sep 30, 2025 | -8.83 Mn |
| Sep 30, 2025 | -8.83 Mn |
| Jun 30, 2025 | 3.73 Mn |
| Jun 30, 2025 | 3.73 Mn |
| Mar 31, 2025 | -2.23 Mn |
| Mar 31, 2025 | -2.23 Mn |
| Dec 31, 2024 | 2.39 Mn |
| Dec 31, 2024 | 2.39 Mn |
| Sep 30, 2024 | -3.03 Mn |
| Sep 30, 2024 | -3.03 Mn |
| Jun 30, 2024 | 6.78 Mn |
| Jun 30, 2024 | 6.78 Mn |
| Mar 31, 2024 | -7.50 Mn |
| Mar 31, 2024 | -7.50 Mn |